Translational Research

Translational Research

Translational research transforms scientific discoveries arising from fundamental studies into clinical applications to improve outcomes for patients with prostate cancer. Members of this team work together to employ innovative new technologies for biomarker discovery, detection and quantification that have been developed independently in internationally-recognized efforts in Alberta and bring them to bear on a common goal – developing better tests for prostate cancer.

The combination of prognostic biomarkers from distinct aspects of prostate cancer progression resulted in a test that is more sensitive, more accurate and more cost effective than current tests for prostate cancer.

Our overall goal is to improve patient outcomes and quality of life by translating novel tests to the clinic that are more sensitive, more accurate and more cost-effective than current tests for prostate cancer. No one dies from prostate cancer that is localized to the prostate – the spread, or metastasis, of prostate cancer is what makes it so dangerous. The five year survival rate for localized prostate cancer in North America is close to 100%, yet this drops to 30% for metastatic disease. The metastasis of prostate cancer is driven primarily by changes in growth factors, extracellular proteases, and the cell migration machinery. Biomarkers that are involved in these processes are prognostic for metastatic prostate cancer and their integration into a single powerful test are the focus of this multi-disciplinary team.

Our team is integrating internationally-recognized efforts in the characterization of tumour cell migration, growth factor signaling and protease-activated receptors to develop novel multiplex tests to more accurately predict outcomes in prostate cancer.

translational-research-image

Member of the APCaRI Training Program will present a poster at CARO ASM 2017 – Toronto

Congratulations to Dr. Deepak Dinakaran for getting his abstract “Comparison of Post-Radiotherapy Prostate Specific Antigen drop kinetics between External Beam Radiotherapy and Brachytherapy” accepted as a poster presentation at the Canadian Association of Radiation Oncology Annual Scientific Meeting (CARO ASM) 2017.

The 2017 CARO Annual Scientific Meeting will be held at the Hilton Toronto in Toronto, ON September 13-16, 2017.  This conference is for Radiation Oncologists, Medical Physicists, Radiation Therapists, Basic Science Researchers, Oncology Nurses, Administrators, as well as their trainees. All healthcare professionals involved in the care of oncology patients are also welcome to attend.

Dr. Dinakaran extracted and analyzed clinical data from the Alberta Prostate Cancer Registry for this study.

- Unknown